«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:

2018年02期

页码:

79-83

栏目:

基础研究

出版日期:

2018-03-25

文章信息/Info

Title:

Mechanism of astragalus polysaccharide therapy in improving myocardial lipid toxicity in db/db diabetic obese mice

作者:

陈蔚; 鞠婧; 孙奇林; 王浩; 王莉英; 杨叶虹; 叶红英; 李益明; 张玉

200040 上海,复旦大学附属华山医院老年科(陈蔚,鞠婧,孙奇林,张玉),内分泌代谢科(杨叶虹,叶红英, 李益明); 200032 上海,复旦大学基础医学实验教学中心(王浩,王莉英)

Author(s):

CHEN Wei¹;  JU Jing¹;  SUN Qilin¹;  WANG Hao²;  WANG Liying²;  YANG Yehong³;  YE Hongying³;  LI Yiming³;  ZHANG Yu¹.

1. Department of Geriatrics, Huashan Hospital, Fudan University, Shanghai 200040; 2. Experimental Teaching Center of Basic Medicine, Fudan University, Shanghai 200032; 3. Department of Endocrinology, Huashan Hospital, Fudan University, Shanghai 200040, China

关键词:

黄芪多糖;  糖尿病;  脂肪酸;  心肌病

Keywords:

Astragalus polysaccharides;  Diabetes mellitus;  Fatty acids;  Cardiomyopathy

分类号:

-

DOI:

10.3969/j.issn.1673-6583.2018.02.005

文献标识码:

-

摘要:

目的:探讨黄芪多糖对糖尿病心肌脂肪酸代谢紊乱及脂毒性的影响。方法:将5周龄的雄性2型糖尿病模型db/db小鼠按照随机数字表法分为黄芪多糖组、二甲双胍组、糖尿病组,每组8只,每日分别经胃管鼻饲黄芪多糖2 000 mg/kg、二甲双胍2 000 mg/kg、等量生理盐水,共12周。8只同龄C57BL/6J小鼠设为正常组,每日经胃管鼻饲等量生理盐水。采用超声心动图检测各组小鼠的心脏功能情况,Bligh-Dyer法和电喷雾电离质谱(ESIMS)方法检测心肌组织三酰甘油沉积情况,微型正电子发射断层显像技术检测心肌脂肪酸的摄取利用和氧化代谢指标,western blot法检测脂肪酸代谢关键酶的蛋白表达水平。结果:(1)与正常组相比,糖尿病组小鼠左室舒张末期内径(LVEDD)和左室收缩末期内径(LVESD)显著升高,左室短轴缩短率(FS)显著降低(P均<0.05); 黄芪多糖组上述指标较糖尿病组有显著改善(P均<0.05); 二甲双胍组上述指标与糖尿病组相比差异无统计学意义。(2)与正常组相比,糖尿病组小鼠心肌组织的脂肪酸摄取利用率、游离脂肪酸氧化率、三酰甘油含量和三酰甘油各亚型含量显著升高(P均<0.05); 黄芪多糖组上述指标较糖尿病组显著降低(P均<0.05); 二甲双胍组上述指标与糖尿病组相比差异无统计学意义。(3)与正常组相比,糖尿病组小鼠心肌组织中氧化物酶体增殖物激活受体α(PPARα)、心肌组织内肌肉型-肉毒碱棕榈酰转移酶-1(M-CPT-1)和乙酰辅酶A氧化酶的蛋白表达水平均显著升高(P均<0.05); 黄芪多糖组上述蛋白的表达水平与糖尿病组相比均显著降低(P均<0.05); 二甲双胍组上述蛋白的表达水平与糖尿病组相比差异无统计学意义。结论:黄芪多糖可显著改善糖尿病组小鼠的心脏功能,降低糖尿病小鼠心肌组织的脂肪酸摄取利用率、游离脂肪酸氧化率和三酰甘油含量,控制糖尿病小鼠心肌脂肪酸代谢相关蛋白处于正常水平,从而改善糖尿病心肌脂肪酸代谢紊乱及脂毒性。

Abstract:

Objective:To explore the effect of astragalus polysaccharide(APS)on fatty acid metabolism and lipid toxicity in diabetic cardiomyopathy.Methods:The 5 weeks old male type 2 diabetes model db/db mice were divided into astragalus polysaccharides group, metformin group and diabetic group, according to the random number table method. Each group had 8 rats, which were given APS 2000 mg/kg, metformin 2000 mg/kg and an equal amount of saline through nasogastric tube for 12 weeks respectively. Eight same-age C57BL/6J mice were set as normal group and fed with the same amount of normal saline. Cardiac function was examined by echocardiography in each group. Bligh-Dyer and ESIMS were used to detect myocardial triglyceride deposition. Micro-positron emission tomography was used to detect myocardial fatty acid uptake and index of oxidative metabolism. Western blot was used to detect the protein expression level of key enzymes involved in the metabolism of fatty acids.Results:(1)The LVEDD and LVESD were increased significantly, while the LV fractional shortening(FS)were decreased significantly in diabetic group compared with those in normal group(all P<0.05). The above indexes of APS group were significantly improved compared with those of diabetic group(all P<0.05). There was no significant difference in above indexes between metformin group and diabetic group.(2)Compared with the normal group, the fatty acid uptake rate, the free fatty acid oxidation rate, the triglyceride content and the triglyceride subtypes in diabetic group were significantly increased(all P<0.05)The above indexes in APS group were significantly lower than those in diabetic group(all P<0.05). There was no significant difference in above indexes between the metformin group and diabetic group.(3)Compared with normal group, the protein expression levels of PPARα、 M-CPT-1 and ACO in myocardium were significantly increased in diabetic group(all P<0.05). The expression of these proteins was significantly lower in APS group than those in diabetic group(all P<0.05). There was no significant difference in protein expression between the metformin group and diabetic group.Conclusions:APS can improve fatty acid metabolism in diabetic myocardium, including improving cardiac function, decreasing fatty acid uptake and utilization rate, free fatty acid oxidation rate and triglyceride content in the myocardium of diabetic mice, and controlling the fatty acid metabolism related proteins in the myocardium of diabetic mice at normal levels.

参考文献/References

[1] Yang WY, Lu JM, Weng JP, et al. Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010, 362(12):1090-1101.
[2] Mandavia CH, Aroor AR, Demarco VG, et al. Molecular and metabolic mechanisms of cardiac dysfunction in diabetes[J]. Life Sci, 2013, 92(11):601-608.
[3] Goyal BR, Mehta AA. Diabetic cardiomyopathy: pathophysiological mechanisms and cardiac dysfuntion[J]. Hum Exp Toxicol, 2013, 32(6):571-590.
[4] Chen W, Li YM, Yu MH. Effects of astragalus polysaccharides on chymase, angiotensin-converting enzyme and angiotensin Ⅱ in diabetic cardiomyopathy in hamsters[J]. J Int Med Res, 2007, 35(6):873-877.
[5] Chen W, Li Y, Yu M. Astragalus polysaccharides: an effective treatment for diabetes prevention in NOD mice[J]. Exp Clin Endocrinol Diabetes, 2008, 116(8):468-474.
[6] Chen W, Li YM, Yu MH. Astragalus polysaccharides inhibited diabetic cardiomyopathy in hamsters depending on suppression of heart chymase activation[J]. J Diabetes Complications, 2010, 24(3):199-208.
[7] Chen W, Yu MH, Li YM, et al. Beneficial effects of astragalus polysaccharides treatment on cardiac chymase activities and cardiomyopathy in diabetic hamsters[J]. Acta Diabetol, 2010, 47(Suppl 1):35-46.
[8] Chen W, Xia YP, Chen WJ, et al. Improvement of myocardial glycolipid metabolic disorder in diabetic hamster with Astragalus polysaccharides treatment[J]. Mol Biol Rep, 2012, 39(7):7609-7615.
[9] Chen W, Xia Y, Zhao X, et al. The critical role of Astragalus polysaccharides for the improvement of PPARα[correction of PPRAα]-mediated lipotoxicity in diabetic cardiomyopathy[J]. PLoS One, 2012, 7(10):e45541.
[10] Chen W, Chen WJ, Xia YP, et al. Therapy with Astragalus polysaccharides rescues lipotoxic cardiomyopathy in MHC-PPAR alpha mice[J]. Mol Biol Rep, 2013, 40(3):2449-2459.
[11] Finck BN, Lehman JJ, Leone TC, et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus[J]. J Clin Invest, 2002, 109(1):121-130.
[12] Orasanu G, Ziouzenkova O, Devchand PR, et al. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice[J]. J Am Coll Cardiol, 2008, 52(10):869-881.
[13] Giacco F, Brownlee M. Oxidative stress and diabetic complications[J]. Circ Res, 2010, 107(9):1058-1070.
[14] Sharma V, Mcneill JH. Diabetic cardiomyopathy: where are we 40 years later?[J]. Can J Cardiol, 2006, 22(4):305-308.
[15] Boudina S, Abel ED. Diabetic cardiomyopathy revisited[J]. Circulation, 2007, 115(25):3213-3223.
[16] Watanabe K, Thandavarayan RA, Harima M, et al. Role of differential signaling pathways and oxidative stress in diabetic cardiomyopathy[J]. Curr Cardiol Rev, 2010, 6(4):280-290.
[17] Yang J, Sambandam N, Han X, et al. CD36 deficiency rescues lipotoxic cardiomyopathy[J]. Circ Res, 2007, 100(8):1208-1217.
[18] Asai T, Okumura K, Takahashi R, et al. Combined therapy with PPARalpha agonist and L-carnitine rescues lipotoxic cardiomyopathy due to systemic carnitine deficiency[J]. Cardiovasc Res, 2006, 70(3):566-577.
[19] Finck BN, Han X, Courtois M, et al. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content[J]. Proc Natl Acad Sci U S A, 2003, 100(3):1226-1231.
[20] Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis[J]. Circ Res, 2006, 98(5):596-605.

备注/Memo

备注/Memo:

基金项目:国家自然科学基金(81473460)
通信作者:陈蔚,Email:chenwei_0424@163.com

常用功能

更新日期/Last Update: 2018-04-20